Publications from Buckingham Institute for Translational Medicine

Peer Reviewed Publications

Harzallah A, Hammami M, Kępczyńska MA, Hislop DC, Arch JR, Cawthorne MA, Zaibi MS (2016). Comparison of potential preventive effects of pomegranate flower, peel and seed oil on insulin resistance and inflammation in high-fat and high-sucrose diet-induced obesity mice model. Arch Physiol Biochem 122(2), 75-87. doi: 10.3109/13813455.2016.1148053

Martin-Gronert MS, Stocker CJ, Wargent ET, Cripps RL, Garfield AS, Jovanovic Z, D’Agostino G, Yeo GS, Cawthorne MA, Arch JR, Heisler LK, Ozanne SE (2016). 5-HT2A and 5-HT2C receptors as hypothalamic targets of developmental programming in male rats. Dis Model Mech 9(4), 401-12. doi: 10.1242/dmm.023903

Hansen SV, Christiansen E, Urban C, Hudson BD, Stocker CJ, Due-Hansen ME, Wargent ET, Shimpukade B, Almeida R, Ejsing CS, Cawthorne MA, Kassack MU, Milligan G, Ulven T (2016). Discovery of a potent free fatty acid 1 receptor agonist with low lipophilicity, low polar surface area, and robust in vivo efficacy. J Med Chem 59(6), 2841-6. doi: 10.1021/acs.jmedchem.5b01962

Yavari A, Stocker CJ, Ghaffari S, Wargent ET, Steeples V, Czibik G, Pinter K, Bellahcene M, Woods A, Martínez de Morentin PB, Cansell C, Lam BY, Chuster A, Petkevicius K, Nguyen-Tu MS, Martinez-Sanchez A, Pullen TJ, Oliver PL, Stockenhuber A, Nguyen C, Lazdam M, O’Dowd JF, Harikumar P, Tóth M, Beall C, Kyriakou T, Parnis J, Sarma D, Katritsis G, Wortmann DD, Harper AR, Brown LA, Willows R, Gandra S, Poncio V, de Oliveira Figueiredo MJ, Qi NR, Peirson SN, McCrimmon RJ, Gereben B, Tretter L, Fekete C, Redwood C, Yeo GS, Heisler LK, Rutter GA, Smith MA, Withers DJ, Carling D, Sternick EB, Arch JR, Cawthorne MA, Watkins H, Ashrafian H (2016). Chronic activation of γ2 AMPK induces obesity and reduces β cell function. Cell Metab 23(5), 821-836. doi: 10.1016/j.cmet.2016.04.003

Arch JR (2015). Horizons in the pharmacotherapy of obesity. Curr Obes Rep 4(4), 451-9. doi: 10.1007/s13679-015-0177-4

Alomar SY, Zaibi MS, Kępczyńska MA, Gentili A, Alkhuriji A, Mansour L, Dar JA, Trayhurn P (2015). PCR array and protein array studies demonstrate that IL-1β (interleukin-1β) stimulates the expression and secretion of multiple cytokines and chemokines in human adipocytes. Arch Physiol Biochem 121(5), 187-93. doi: 10.3109/13813455.2015.1087034

Christiansen E, Watterson KR, Stocker CJ, Sokol E, Jenkins L, Simon K, Grundmann M, Petersen RK, Wargent ET, Hudson BD, Kostenis E, Ejsing CS, Cawthorne MA, Milligan G, Ulven T (2015). Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Br J Nutr 113(11), 1677-88. doi: 10.1017/S000711451500118X

Silvestri C, Paris D, Martella A, Melck D, Guadagnino I, Cawthorne M, Motta A, Marzo VD (2015). Two non-psychoactive cannabinoids reduce intra-cellular lipid levels and inhibit hepatosteatosis. J Hepatol 62(6), 1382-1390. doi: 10.1016/j.jhep.2015.01.001

Butler J, Smyth N, Broadbridge R, Council CE, Lee AG, Stocker CJ, Hislop DC, Arch JR, Cawthorne MA, Malcolm East J (2015). The effects of sarcolipin over-expression in mouse skeletal muscle on metabolic activity. Arch Biochem Biophys 569C, 26-31. doi: 10.1016/j.abb.2015.01.027

Wargent ET, Zaibi MS, O’Dowd JF, Cawthorne MA, Wang SJ, Arch JR, Stocker CJ (2015). Evidence from studies in rodents and in isolated adipocytes that agonists of the chemerin receptor CMKLR1 may be beneficial in the treatment of type 2 diabetes. Peer J 3, e753. doi: 10.7717/peerj.753

Ibrahim M, Jassim S, Cawthorne M, Langlands K (2014). A MATLAB tool for pathway enrichment using a topology-based pathway regulation score. BMC Bioinformatics. 15(1):358. doi: 10.1186/s12859-014-0358-2

Rumberger JM, Arch JR, Green A (2014). Butyrate and other short-chain fatty acids increase the rate of lipolysis in 3T3-L1 adipocytes. Peer J 2, e611. doi: 10.7717/peerj.611

Ngala RA, Zaibi MS, Langlands K, Stocker CJ, Arch JR, Cawthorne MA (2014).  Stimulation of glucose uptake in murine soleus muscle and adipocytes by 5-(4-phenoxybutoxy)psoralen (PAP-1) may be mediated by Kv1.5 rather than Kv1.3.  Peer J 2, e614. doi: 10.7717/peerj.614

Harikumar PE, Selway JL, Chu A, Langlands K (2014).  Collagen remodelling and peripheral immune cell recruitment characterises the cutaneous Langerhans Cell Histiocytosis (LCH) microenvironment.  Int J Dermatol 54(1), e7-13. doi: 10.1111/ijd.12375

Kępczyńska MA, Wargent ET, Cawthorne MA, Arch JRS, O’Dowd JF, Claire J. Stocker CJ (2013). Circulating levels of the cytokines IL10, IFN gamma and resistin in an obese mouse model of developmental programming.  J DOHaD 4(6), 491-498. doi:10.1017/S2040174413000263

Osman OS, Selway JL, Kępczyńska MA, Stocker CJ, O’Dowd JF, Cawthorne MA, Arch JRS, Jassim S, Langlands K (2013).  A novel automated image analysis method for accurate adipocyte quantification. Adipocyte 2(3), 160-164. doi: 10.4161/adip.24652

Selway JL, Kurczab T, Kealey T, Langlands K (2013).  Toll-like receptor 2 activation and comedogenesis: implications for the pathogenesis of acne.  BMC Dermatol 13(10).  doi: 10.1186/1471-5945-13-10

Osman OS, Selway JL, Harikumar PE, Stocker CJ, Wargent ET, Cawthorne MA, Jassim S, Langlands K (2013).  A novel method to assess collagen architeture in skin.  BMC Bioinformatics 14, 260.  doi: 10.1186/1471-2105-14-260

Christiansen E, Due-Hansen ME, Urban C, Grundmann M, Schmidt J, Hansen SV, Hudson BD, Zaibi M, Markussen SB, Hagesaether E, Milligan G, Cawthorne MA, Kostenis E, Kassack MU, Ulven T (2013).  Discovery of a potent and selective free Fatty Acid receptor 1 agonist with low lipophilicity and high oral bioavailability.  J Med Chem 56(3), 982-992. doi: 10.1021/jm301470a

Trayhurn P (2013).  Hypoxia and adipose tissue function and dysfunction in obesity.  Physiol Rev 93(1), 1-21. doi: 10.1152/physrev.00017.2012

Wargent ET, Zaibi MS, Silvestri C, Hislop DC, Stocker CJ, Stott CG, Guy GW, Duncan M, Di Marzo V, Cawthorne MA (2013).  The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.  Nutr Diabetes 3, e68. doi: 10.1038/nutd.2013.9

Arch JR, Trayhurn P (2013).  Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification.  Front Physiol 8:4:64.  doi: 10.3389/fphys.2013.00064

Mejhert  N, Wilfling F, Esteve D, Galitzky J, Pellegrinelli V, Kolditz C-I, Viguerie N, Tordjman J, Näslund E, Trayhurn P, Lacasa D, Dahlman I, Stich V, Lång P, Langin D, Bouloumié A, Clément K, Rydén M (2013).  Semaphorin 3C is a novel adipokine linked to extracellular matrix composition.  Diabetologia 56, 1792–1801.  doi: 10.1007/s00125-013-2931-z

Ngala RA, O’Dowd JF, Stocker CJ, Cawthorne MA, Arch JR (2013).  β2-adrenoceptor agonists can both stimulate and inhibit glucose uptake in mouse soleus muscle through ligand-directed signalling.  Naunyn Schmiedebergs Arch Pharmacol 386(9), 761-763. doi: 10.1007/s00210-013-0860-5

Christiansen E, Hansen SV, Urban C, Hudson BD, Wargent ET, Grundmann M, Jenkins L, Zaibi M, Stocker CJ Ullrich S, Kostenis, Kassack MU, Milligan G, Cawthorne ME, Ulven T (2013).  Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Med Chem Lett 4(5), 441-445. doi:  10.1021/ml4000673

Stolarzyk E, Vong CT, Perucha E, Jackson I, Cawthorne MA, Wargent ET, Powell N, Canavan JB, Lord GM, Howard JK (2013).  Improved insulin sensitivity despite increased visceral adiposity in mice deficient for the immune cell transcription factor T-bet.  Cell Metab 17(4), 520-33. doi:10.1016/j.cment. 2013.02.19

O’Dowd JF and Stocker CJ. (2013).  Endocrine pancreatic development: impact of obesity and diet.  Front Physiol 4, 170. doi:  10.3389/fphys.2013.00170

Ibrahim M, Jassim S, Cawthorne MA, Langlands K (2012). Integrating pathway enrichment and gene network analysis provides accurate disease classification. In Proceedings of the International Conference on Bioinformatics Models, Methods and Algorithms, Portugal, 1-4 Feb 2012, 156-163 doi.5220/0003767901560163

Ibrahim M, Jassim S, Cawthorne MA, Langlands K (2012). A topology-based score for pathway enrichment. J Comp Biol 19(5), 563-574. full paper

Stocker CJ, Wargent ET, Martin-Gronert MS, Cripps RL, O’Dowd JF, Zaibi MS, Cottrell EC, Mercer JG, Duncan JS, Cawthorne MA, Ozanne SE, Arch JR (2012). Leanness in postnatally nutritionally programmed rats is associated with increased sensitivity to leptin and a melanocortin receptor agonist and decreased sensitivity to neuropeptide Y.  Int J Obes (Lond) 36(8), 1040-1046. doi: 10.1038/ijo.2011.226

Christiansen E, Due-Hansen ME, Urban C, Grundmann M, Schroder R, Hudson BD, Milligan G, Cawthorne MA, Kostenis E, Kassack MU, Ulven T (2012).  Free fatty acid receptor 1 (FFA1/GPR40) agonists:  mesylpropoxy appendage lowers lipophilicity and improves ADME properties.  J Med Chem 55(14), 6624-6628. doi: 10.1021/jm3002026

Wargent ET, O’Dowd J, Zaibi M, Gao D, Bing C, Trayhurn P, Cawthorne M, Arch JR, Stocker CJ (2012). Contrasts between the effects of zinc-α2-glycoprotein, a putative β3/2-adrenoceptor agonist, and the β3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (ob/ob) mice. J Endocrinol 216(2), 157-168. doi: 10.1530/JOE-12-0402

Bellahcene M, O’Dowd JF, Wargent ET, Zaibi MS, Hislop DC, Ngala RA, Smith DM, Cawthorne MA, Stocker CJ, Arch JR (2012). Male mice that lack the G-protein-coupled receptor GPR41 have low energy expenditure and increased body fat content. Br J Nutr 109(10), 1755-1764. doi: 10.1017/S0007114512003923

Rkhzay-Jaf J, O’Dowd JF, Stocker CJ (2012). Maternal Obesity and the Fetal Origins of the Metabolic Syndrome. Curr Cardiovasc Risk Rep 6(5), 487-495. doi:  10.1007/s12170-012-0257-x

O’Hara A, Lim FL, Mazzatti DJ, Trayhurn P (2012).  Stimulation of inflammatory gene expression in human preadipocytes by macrophage-conditioned medium: upregulation of IL-6 production by macrophage-derived IL-1β.  Mol Cell Endocrinol 349(2), 239-247. doi: 10.1016/j.mce.2011.10.031

Ding C, Gao D, Wilding J, Trayhurn P, Bing C (2012).  Vitamin D signalling in adipose tissue.  Br J Nutr 108(11), 1915-1923.  doi: 10.1017/S0007114512003285

Gao D, Trayhurn P, Bing C (2012).  1,25-Dihydroxyvitamin D(3) inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes.  Int J Obes (Lond), 37(3), 357-365. doi: 10.1038/ijo.2012.53

Mazzatti D, Lim FL, O’Hara A, Wood IS, Trayhurn P (2012).  A microarray analysis of the hypoxia-induced modulation of gene expression in human adipocytes.  Arch Physiol Biochem 118(3), 112-20. doi: 10.3109/13813455.2012.654611

Ibrahim M, Jassim S, Cawthorne MA, Langlands K (2011). A pathway-based gene selection method provides accurate disease classification. IJDS, 2 (4), 566–573. full paper

Ngala RA, Stocker CJ, Roy AG, Hislop D, Wargent E, Hassall DG, Harling JD, Billin AN, Willson TM, Arch JR, Cawthorne MA (2011).  A new, highly selective murine peroxisone proliferator-activated receptor d agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice.  Diabetes Obes Metab 13(5), 455-464. doi: 10.1111/j.1463-1326.2011.01371.x

Zaibi MS, Stocker CJ, O’Dowd J, Davies A, Bellahcene M, Cawthorne MA, Brown AJ, Smith DM, Arch JR (2010).   Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids.  FEBS Lett 584(11), 2381-2386. doi: 10.1016/j.febslet.2010.04.027

Mracek T, Gao D, Tzanavari T, Bao Y, Xiao X, Stocker CJ, Trayhurn P, Bing C (2010). Downregulation of zinc-α2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-α in adipocytes. J Endocrinol 204(2), 165-172. doi: 10.1677/JOE-09-0299

Ngala RA, O’Dowd J, Wang SJ, Stocker C, Cawthorne MA, Arch JRS (2009). β2-Adrenoceptors and non-β-adrenoceptors mediate effects of BRL37344 and clenbuterol on glucose uptake in soleus muscle: studies using knockout mice. Br J Pharmacol 158(7), 1676–82. doi:10.1111/j.1476-5381.2009.00472.x

Cornick CL, Strongitharm BH, Sassano G, Rawlins C, Mayes AE, Joseph AN, O’Dowd J, Stocker C, Wargent E, Cawthorne MA, Brown AL, Arch JRS (2009). Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice. J Nutr Biochem 20(10), 806-815. doi:10.1016/j.jnutbio.2008.07.010

Stocker CJ, Cawthorne MA (2008). The influence of leptin on early life programming of obesity. Trends Biotechnol. 26(10):545–551. doi:10.1016/j.tibtech.2008.06.004

Arch JRS (2008). The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β3-adrenoceptor agonists. Naunyn-Schmied Arch Pharmacol 378(2), 225–240. doi:10.1007/s00210-008-0271-1

Ngala RA, O’Dowd J, Wang SJ, Agarwal A, Stocker C, Cawthorne MA, Arch JRS (2008). Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and β2-adrenoceptor mechanisms. Br J Pharmacol155(3), 395–406. doi:10.1038/bjp.2008.244

Fyfe MCT, White JR, Taylor A, Chatfield R, Wargent E, Printz RL, Sulpice T, McCormack JG, Procter MJ, Reynet C, Widdowson PS, Wong-Kai-In P (2007). Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 50(6), 1277–1287. doi:10.1007/s00125-007-0646-8

Clapham JC, Arch JRS (2007). Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes Metab 9(3), 259–275. doi:10.1111/j.1463-1326.2006.00608.x

Schmid GM, Meda P, Caille D, Wargent E, O’Dowd J, Hochstrasser DF, Cawthorne MA, Sanchez J-C (2007). Inhibition of insulin secretion by betagranin, a N-terminal chromogranin A fragment. J Biol Chem 282(7), 12717–12724. doi:10.1074/jbc.M700788200

Cawthorne MA (2007). Opportunities and challenges for the development of pharmacological therapies for obesity treatment. Obes Rev 8 (Suppl 1), 131–136. doi:10.1111/j.1467-789X.2007.00332.x

Wang SJ, Cornick C, O’Dowd J, Cawthorne MA, Arch JRS (2007). Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet. Lipids Health Dis 6(2).  doi:10.1186/1476-511X-6-2

Stocker CJ, Wargent E, O’Dowd J, Cornick C, Speakman JR, Arch JRS, Cawthorne MA (2007). Prevention of diet-induced obesity and impaired glucose tolerance in rats following administration of leptin to their mothers. Am J Physiol Regul Integr Comp Physiol 292, R1810–R1818. doi:10.1152/ajpregu.00676.2006

Arch JRS. Comment on: ‘Schmidt MI, Duncan BB, Vigo A et al. (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia 49:2086-2096.’ Diabetologia 2007 Jan;50(1):239–240. doi:10.1007/s00125-006-0523-x.

McLellan AS, Kealey T, Langlands K (2006). An E box in the exon 1 promoter regulates insulin-like growth factor-I expression in differentiating muscle cells. Am J Physiol Cell Physiol 291(2), C300–C307. doi:10.1152/ajpcell.00345.2005

Arch JRS, Hislop D, Wang SJY, Speakman JR (2006). Some mathematical and technical issues in the measurement and interpretation of open-circuit indirect calorimetry in small animals. Int J Obes 30, 1322–1331. doi:10.1038/sj.ijo.0803280

Wang SJY, Birtles S, de Schoolmeester J, Swales J, Moody G, Hislop D, O’Dowd J, Smith DM, Turnbull AV, Arch JRS (2006). Inhibition of 11β-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 49(6), 1333–1337. doi:10.1007/s00125-006-0239-y

Yang CL, Kurczab T, Down G, Kealey T, Langlands K (2005). Gene expression profiling of the ageing rat vibrissa follicle. Br J Dermatol 153(1), 22–28.

Stocker CJ, Arch JRS, Cawthorne MA (2005). Fetal origins of insulin resistance and obesity. Proc Nutr Soc 64(2), 143–151 doi:10.1079/PNS2005417

Wargent E, Stocker C, Augstein P, Heinke P, Meyer A, Hoffmann T, Subramanian A, Sennitt MV, Demuth H-U, Arch JRS, Cawthorne MA (2005). Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obes Metab 7(2), 170–181. doi:10.1111/j.1463-1326.2004.00383.x

Arch JRS (2005). Central regulation of energy balance: inputs, outputs and leptin resistance. Proc Nutr Soc 64(1), 39–46. doi:10.1079/PNS2004407

Wargent E, Sennitt MV, Stocker C, Mayes AE, Brown L, O’Dowd J, Wang SJY, Einerh AWC, Mohede I, Arch JRS, Cawthorne MA (2005). Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Lipids Health Dis 4, 3. doi:10.1186/1476-511X-4-3

Arch JRS (2004). Do low-affinity states of β-adrenoceptors have roles in physiology and medicine? Br J Pharmacol 143, 517–518. doi:10.1038/sj.bjp.0705991

Pearce NJ,  Arch JR, Clapham JC, Coghlan MP, Corcoran SL, Lister CA, Llano A, Moore GB, Murphy GJ, Smith SA, Taylor CM, Yates JW, Morrison AD, Harper AJ, Roxbee-Cox L, Abuin A, Wargent E, Holder JC (2004). Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3β on a muscle-specific promoter. Metabolism 53,1322-1330. doi:10.1016/j.metabol.2004.05.008

Schmid GM, Converset V, Walter N,  Sennitt MV, Leung K-Y, Byers H, Ward M, Hochstrasser DF, Cawthorne MA, Sanchez JC (2004). Effect of high-fat diet on the expression of proteins in muscle, adipose tissues, and liver of C57Bl/6 mice. Proteomics 4, 2270-2282. doi: 10.1002/pmic.200300810

Stocker C, O’Dowd J, Morton NM, Wargent E, Sennitt MV, Hislop D, Glund S, Seckl JR, Arch JRS, Cawthorne MA (2004). Modulation of susceptibility to weight gain and insulin resistance in low birthweight rats by treatment of their mothers with leptin during pregnancy and lactation. Int J Obes 28, 129-136. doi:10.1038/sj.ijo.0802476

Sanchez JC, Converset V, Nolan A, Schmid G, Wang S, Heller M, Sennitt MV, Hochstrasser DF, Cawthorne MA (2003). Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. Proteomics 3, 1500-1520. doi: 10.1002/pmic.200300484

Wang S, Subramaniam A, Cawthorne MA, Clapham JC (2003). Increased fatty acid oxidation in transgenic mice overexpressing UCP3 in skeletal muscle. Diabetes Obes Metab 5, 295-301. doi: 10.1046/j.1463-1326.2003.00273.x

Echtay KS, Esteves TC, Pakay JL, Jekabsons MB, Lambert AJ, Portero-Otin M, Pamplona R, Vidal-Puig AJ, Wang S, Roebuck SJ, Brand MD (2003). A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling. EMBO J 22, 4103-4110. doi: 10.1093/emboj/cdg412

Arch JRS (2002). Lessons in obesity from transgenic animals. J Endocrinol Invest 25, 867-875. doi:10.1007/BF03344050

Sanchez J-C, Converset V, Nolan A, Schmid G, Wang S, Heller M, Sennitt MV, Hochstrasser DF, Cawthorne MA (2002). Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57Bl/6 lep/lep mice. Mol Cell Proteomics 1, 509-516. doi:10.1074/mcp.M200033-MCP200

Smart D, Haynes AC, Williams G, Arch JRS (2002). Orexins and the treatment of obesity. Eur J Pharmacol 440, 199-212. doi:10.1016/S0014-2999(02)01429-2

Arch JRS (2002). b3-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 440, 99-107. doi:10.1016/S0014-2999(02)01421-8

Wang S, Cawthorne MA, Clapham JC (2002). Enhanced diabetogenic effect of streptozotocin in mice overexpressing UCP-3 in skeletal muscle. Ann NY Acad Sci 967, 112-119. doi: 10.1111/j.1749-6632.2002.tb04269.x

Haynes AC, Chapman H, Taylor C, Moore GB, Cawthorne MA, Tadayyon M, Clapham JC, Arch JRS (2002). Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept 104, 153-159. doi:10.1016/S0167-0115(01)00358-5

Cai XJ, Liu HL, Evans M, Clapham JC, Wilson S, Arch JRS, Williams G (2002). Orexins and feeding: special occasion or everyday occurrence? Regul Pept 104, 1-9. doi:10.1016/S0167-0115(01)00343-3

Emilsson V, O’Dowd J, Nolan AL, Cawthorne MA (2001). Hexosamines and nutrient excess induce leptin production and leptin receptor activation in pancreatic islets and clonal beta-cells. Endocrinology 142, 4414-4419.  doi:10.1210/endo.142.10.8414

Sanchez J-C, Chiappe D, Converset V, Hoogland C, Binz P-A, Paesano S, Appel RD, Wang S, Sennitt M, Nolan A, Cawthorne MA, Hochstrasser DF (2001). The mouse SWISS-2D PAGE database: a tool for proteomics study of diabetes and obesity. Proteomics 1, 136-163. doi:10.1002/1615-9861(200101)1:1<136::AID-PROT136>3.3.CO;2-T 

Emilsson V, O’Dowd J, Wang S, Liu Y-L, Sennitt M, Heyman R, Cawthorne MA (2000). The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 49, 1610-1615. doi:10.1053/meta.2000.18692

Islam MS, Sjoholm A, Emilsson V (2000). Fetal pancreatic islets express functional leptin receptors and leptin stimulates proliferation of fetal islet cells. Int J Obesity Relat Metab Disord 24, 1246-1253. doi:10.1038/sj.ijo.0801370

Board M, Doyle P, Cawthorne MA (2000). BRL 37344, but not CGP 12177, stimulates fuel oxidation by soleus muscle in vitro. Eur J Pharmacol 406, 33-40. doi:10.1016/S0014-2999(00)00671

Liu Y-L, Sennitt MV, Hislop DC, Crombie DL, Heyman RA, Cawthorne MA (2000). Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats. Int J Obesity 24, 997-1004.

Chamberlain PD, Jennings KH, Paul F, Cordell J, Berry A, Holmes SD, Park J, Chambers J, Sennitt MV, Stock MJ, Cawthorne MA, Young PW, Murphy GJ (1999). The tissue distribution of the human β3-adrenoceptor studied using a monoclonal antibody: direct evidence of the b3-adrenoceptor in human adipose tissue, atrium and skeletal muscle. Int J Obesity 23, 1057-1065.

Emilsson V, Arch JRS, de Groot RP, Lister CA, Cawthorne MA (1999). Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett 455, 170-174.

Morton NM, Emilsson V, de Groot RP, Pallett AL, Cawthorne MA (1999). Leptin signalling in pancreatic islets and clonal insulin-secreting cells. J Mol Endocrinol 22, 173-184.

Morton NM, de Groot RP, Cawthorne MA, Emilsson V (1999). Interleukin-1b activates a short STAT-3 isoform in clonal insulin-secreting cells. FEBS Lett 442, 57-60.

Emilsson V, Summers RJ, Hamilton S, Liu Y-L, Cawthorne MA (1998). The effects of the b3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression. Biochem Biophys Res Commun 252, 450-454.

Morton NM, Emilsson V, Liu Y-L, Cawthorne MA (1998). Leptin action in intestinal cells. J Biol Chem 273, 26194-26201.

Cawthorne MA, Morton NM, Pallett AL, Liu Y-L, Emilsson V (1998). Peripheral metabolic actions of leptin. Proc Nutr Soc 57, 449-453.

Sennitt MV, Kaumann AJ, Molenaar P, Beeley LJ, Young PW, Kelly J, Chapman H, Henson SM, Berge JM, Dean DK, Kotecha NR, Morgan HKA, Rami HK, Ward RW, Thompson M, Wilson S, Smith SA, Cawthorne MA, Stock MJ, Arch JRS (1998). The contribution of classical ( b1/2 ) and atypical b-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel b3-adrenoceptor agonists of different selectivities. J Pharm Exp Therap 285, 1084-1095.

Md. S. Islam, N.M. Morton, A. Hansson and V. Emilsson (1997). Rat insulinoma-derived pancreatic b-cells express a functional leptin receptor that mediates a proliferative response. Biochem. Biophys. Res. Commun. 238, 851-855.

A.L. Pallett, N.M. Morton, M.A. Cawthorne and V. Emilsson (1997). Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. Biochem. Biophys. Res. Commun. 238, 267-270.

Y.L. Liu, V. Emilsson and M.A. Cawthorne (1997). Leptin inhibits glycogen synthesis in the isolated soleus muscle of obese (ob/ob) mice. FEBS Lett. 411, 351-355.

V. Emilsson, Y.L. Liu, M.A. Cawthorne, N.M. Morton and M. Davenport (1997). Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 46, 313-316.

S.L. Pearson, M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B.T. Moore, S.A. Smith and M. Tadayyon (1996). The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPARg and aP2 in adipose tissue of high fat fed rats. Biochem. Biophys. Res. Commun. 229, 752-757.

C. Deng, A. Paoloni-Giacobino, F. Kuehne, O. Boss, J-P. Revelli, M. Moinat, M.A. Cawthorne, P. Muzzin and J-P Giacobino (1996). Respective degree of expression of b1 , b2 and b3 -adrenoceptors in human brown and white adipose tissue. Br. J. Pharmacol. 118, 929-934. L.J. Beeley and M.A. Cawthorne (1996). Lean Prospects. Chem. Britain, May 31-34.

Y-L. Liu, M.A. Cawthorne and M.J. Stock (1996). Biphasic effects of the b-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle. Br. J. Pharmacol. 117, 1355-1361.

Top

Abstracts

The full reference is:

C. Stocker, E. Wargent, J. O’Dowd, R. Ngala, D. Carling, J. Arch and M. Cawthorne (2007). Patterns of postnatal growth impact on the early life programming of energy balance. Early Hum. Dev. 83, Suppl 1, S113, Abs P1-109.

M.A. Cawthorne, E. Wargent, M. Zaibi, C. Stott and S. Wright (2007). The CB-1 antagonist delta-9-tetrahydrocannabivarin (THCV) has anti-obesity activity in dietary-induced obese (DIO) mice. ‘17 Annual Symposium on the Cannabinoids’, Burlington, Vermont, International Cannabinoid Research Society, page 141.

C. Stocker, E. Wargent, K. Smith, J. O’Dowd, J. Arch and M. Cawthorne (2006). Early life programming of appetite by maternal leptin administration. Obes. Rev. 7, Suppl 2, 153, PO0132.

C. Stocker, E. Wargent, J. O’Dowd, D. Carling, J. Arch and M. Cawthorne (2006). Leptin supplementation in early life programmes muscle metabolism. Obes. Rev. 7, Suppl 2, 43, OP0015.

S. Wang, C. Cornick, J. O’Dowd and J. Arch (2005). Energy balance and glucose homeostasis in DGAT-1 homozygous and heterozygous knockout mice on chow and high fat diets. Obes. Res. 13, Suppl 1, A52, 202-P.

M. Cawthorne, E. Wargent, J. O’Dowd, D. Hislop, J. Arch and C. Stocker (2005). Pharmacologic treatment of dams programs offspring to resist diet-induced obesity. Obes. Res. 13, Suppl 1, A1, 2-OR.

J.R.S. Arch , S.J.Y. Wang, S. Birtles, D.M. Smith and A. Turnbull (2005). Effects of an inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 inhibitor on energy balance and glucose homeostasis in diet-induced obesity. Diabetologia 48, Suppl. 1, A238, Abs. 650.

J.F. O’Dowd, C. Cornick, C.J. Stocker, S.J.Y. Wang, M.A. Cawthorne and J.R S. Arch (2005). Identification of preprodynorphin as a pancreatic gene associated with increased susceptibility to diabetes. Diabetologia 48, Suppl. 1, A158, Abs. 425.

M.C.T. Fyfe, M.A. Cawthorne, M.V. Sennitt and R.L. Printz (2005). Antihyperglycemic effects of novel long- and short-acting glucokinase activators (PSN105 and PSN010) in diabetic animals. Diabetes 54, Suppl. 1, A129, Abs. 522-P.

P. Wong-Kai-In, M.A. Cawthorne, E. Wargent and G. Thomas (2005). PSN357, a novel glycogen phosphorylase inhibitor with anti-hyperglycemic efficacy in rodent models of diabetes. Diabetes 54, Suppl. 1, A140, Abs. 567-P.

J.R.S Arch, E. Wargent, M.V. Sennitt, C. Stocker, A.E.Mayes, L. Brown, J. O’Dowd, S. Wang, A.W.C. Einerhand, I. Mohede and M.A. Cawthorne (2005). Prolonged treatment of genetically obese mice with conjugated linoleic acid (CLA) improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Obes. Rev. 6, Suppl. 1, 43, Abs. T2: O103.

J.R. Arch, D. Hislop, S.J. Wang and J. Speakman (2005). Some mathematical and technical issues in open-circuit indirect calorimetry. Physiol. Res. 54(2), 9P.

S. Narayanan, A. Thomas, D. Shah, B. Gopalan, S. Vakkalanka and J. Arch (2004). A novel, orally active dipeptidyl peptidase IV inhibitor potently improves glucose tolerance in mice. Diabetologia 47, Suppl. 1, A285, Abs. 788.

R.A. Ngala, S. Wang, J. O’Dowd, M.A. Cawthorne and J.R.S. Arch (2004). Atypical pharmacology and opposing effects of β-adrenoceptor agonists on glucose uptake in C2C12 cells: similarity with mouse soleus muscle pharmacology. Fundam. Clin. Pharmacol . 18, Suppl. 1, 36, Abs. P 04.22.

J.R.S. Arch (2004). β3-adrenoceptor agonists in obesity and type 2 diabetes: humans vs. rodents. Fundam. Clin. Pharmacol. 18, Suppl. 1, 11, Abs. S 09.2.

K. Smith, E. Wargent, A. Morrison, E. Grau, D. Smart, M. Cawthorne and J.Arch (2004). Normal suppression of feeding by leptin, but enhanced response to CB-1 receptor antagonists in BRS-3 knockout mice. Int. J. Obes. 28, Suppl. 1, S110, Abs. T3:P3-024.

S.J.Y. Wang and J. Arch, (2004). Reduced insulin sensitivity and glucose tolerance in DGAT-1 knockout mice. Int. J. Obes. 28, Suppl. 1, S90, Abs. T2:P2a-058.

N. Degabriele, S. Colombo, A. Medhurst, D. Sunter, J. Mercer and J. Arch, (2004). Insensitivity to tetrahydrocannabinol in rats sensitive to diet-induced obesity. Int. J. Obes. 28, Suppl. 1, S47, Abs. T7d:O1-006.

K. Smith; A. Haynes; H. Chapman, D. Smart and J.R.S. Arch (2004). Central administration of a bombesin receptor-2 agonist abolishes the anorexic effect of bombesin in refed rats Br. Pharmacol. Soc. Pa2 online Vol 2(1), Abs. 029P.

R. A. Ngala; S.J.Y. Wang, M. A. Cawthorne and J. R.S. Arch (2004). Biphasic and atypical pharmacology of glucose uptake in mouse isolated soleus muscle is dependent on the β2-adrenoceptor Br. Pharmacol. Soc. Pa2 online Vol 2(1), Abs. 008P.

S. Wang, M.A. Cawthorne, J.R.S. Arch and J.C. Clapham (2003). Increased adiposity and low leptin in transgenic mice overexpressing UCP-3 in skeletal muscle after long term high fat feeding. Obes. Res. 11(9), Suppl, A30, Abs. 122-OR.

R. Ngala, S. Wang, M.A. Cawthorne and J.R.S. Arch (2003). Atypical pharmacology and opposing effects of β-adrenoceptor agonists on glucose uptake and pyruvate oxidation in skeletal muscle. Diabetologia 46, Suppl. 2, A210, Abs. 606.

G. Schmid, V. Converset, N. Walter, M. Sennitt, M. Ward, M. Cawthorne and J.-C. Sanchez (2003). Effect of high fat diet on the expression of proteins in muscle, adipose tissues and liver of C57Bl/6 mice. Diabetologia 46, Suppl. 2, A207, Abs. 596.

E.T. Wargent, M.V. Sennitt, C.-W. Woon and M.A. Cawthorne (2003). The DPPIV resistant GLP-1 analogue, BIM 51077, improves diabetic control in ZDF rats. Diabetologia 46, Suppl. 2, A169, Abs. 482.

C. Stocker, N.M. Morton, E. Wargent, J. O’Dowd, M.V. Sennitt, D. Hislop, J. Seckl, J.R.S. Arch and M.A. Cawthorne (2003). Leptin administration prevents reduction of placental 11β-hydroxysteroid dehydrogenase-2 associated with maternal protein restriction and prevents obesity in male offspring in a rat model of in utero growth retardation. Pediatr. Res. 53 (6), Suppl., p. 41A, Abs. P.628.

C. Stocker, E. Wargent, J. O’Dowd, M.V. Sennitt, D. Hislop, J.R.S. Arch and M.A. Cawthorne (2003). Maternal leptin administration attenuates high fat diet-induced insulin resistance in female offspring in a rodent model of in utero growth restriction without affecting adiponectin. Pediatr. Res. 53 (6), Suppl., p. 29A, Abs. P.337.

K. Smith, A. Medhurst, C. Stocker, D. Smart and J. Arch (2003). Expression of mRNA for bombesin receptors in hypothalami of fa/fa and fasted rats. Int. J. Obesity 27, Suppl. 1, S65, Abs. P1-091.

C. Stocker, E. Wargent, M.V. Sennitt, J. O’Dowd, D. Hislop, J.R.S. Arch and M.A. Cawthorne (2002). Administration of leptin to pregnant rats fed on a low protein diet prevents high fat diet induced insulin resistance in male offspring. Diabetes 51, Suppl 2, A144, Abs. 582-P.

S. Wang, A. Subramaniam, M.A. Cawthorne and J.C. Clapham (2001). Substrate oxidation in mice over-expressing human UCP-3 in skeletal muscle. Obesity Research 9, Suppl. 3, 113S, Abs. PB28.

C. Stocker, E. Wargent, M. Sennitt, A. Nolan, J. O’Dowd, K. Subramaniam, S. Wang and M. Cawthorne (2001). Maternal leptin administration induces resistance to diet-induced obesity of early growth restricted rats. Diabetologia 44, Suppl 1, A167, Abs 641.

A. Subramaniam, C. Stocker, M.V. Sennitt, S. Wang, A.L. Nolan, L. Brown, M. Bertrand, A. Peilow, A. Mayes and M.A. Cawthorne (2001). Guggul lipid reduces insulin resistance and body weight gain in C57Bl/6 lep/lep mice. Int. J. Obesity 25, Suppl. 2, S24, Abs. O66.

V. Emilsson, J. O’Dowd, A.L. Pallett and M.A. Cawthorne (2001). Hexosamine and nutrient excess induce leptin production and leptin receptor activation in islet b cells. Diabetes 50, Suppl. 2, A343, Abs. 1428.

C. Stocker, E. Wargent, A. Subramaniam, H-U. Demuth, M. Sennitt and M.A. Cawthorne (2001). The dipeptidyl peptidase inhibitor P32/98 improves glucose tolerance in diabetic ZDF rats. Diabetes 50, Suppl. 2, A522, Abs. 2200.

J.-C. Sanchez, D. Chiappe, M.V. Sennitt, V. Rouge, S. Wang, A.L. Pallett, D. Hochstrasser and M. Cawthorne (2000). Effects of the insulin sensitiser drug, rosiglitazone, on the differential expression of obesity-associated liver cytosolic and nuclear proteins of lep/lep mice. Obesity Research 8, Suppl. 1, 125S, Abs. PF38.

M.A. Cawthorne, K. Clavurier, C. Stocker, E. Whittle, A. Subramaniam, I. Rubin and M.V. Sennitt (2000). P57, a plant derived anorexic agent, reduces food intake and normalises blood glucose in ZDF rats. Obesity Research 8, Suppl. 1, 81S. Abs. PB55.

E. Wargent, A.L. Nolan, Y. Shen, J. Dong, J.E. Taylor, M. Culler, B. Morgan, C-W. Woon and M.A. Cawthorne (2000). Insulin secretagogue activity in vitro and in perfused pancreas of dipeptidase IV resistant GLP-1 analogues. Diabetologia 43, Suppl 1, A137, Abs 532.

A.L. Nolan, M.V. Sennitt, E.B. Whittle, C.J. Stocker and M.A. Cawthorne (2000). Acute and chronic effects of exendin-4 on glycaemic control and food intake in diabetic mice. Diabetologia 43, Suppl 1, A148, Abs 572.

M. Board, F. Preitner, J-P. Giacobino and M.A. Cawthorne (2000). The b3 -adrenoceptor agonist, BRL 37344, increases pyruvate and palmitate oxidation in soleus muscle of b3 -KO mice. Int. J. Obesity 24, Suppl 1, Abs 80, S30.

A.C. Haynes, B. Jackson, M.A. Cawthorne, S. Wilson, M. Tadayyon and J.R.S. Arch (2000). Interactions of the orexins and melanin concentrating hormone on feeding. Int. J. Obesity 24, Suppl 1, Abs 101, S37.

J-C. Sanchez, V. Rouge, D. Hochstrasser, M.V. Sennitt, S. Wang, A.L. Pallett and M.A. Cawthorne (2000). Effect of rosiglitazone on the differential expression of diabetes associated proteins in pancreatic islets of C57BI/6J lep/lep mice. Diabetes 49, Suppl 1, Abs 1041-P, A250.

M. Board, P. Doyle and M.A. Cawthorne (1999). Stimulation of oxidative metabolism of isolated skeletal muscle by b3-adrenoceptor (b3-AR) agonists: evidence for the existence of a novel b-AR in murine soleus muscle. Diabetes 48, Suppl 1, Abs 1991.

V. Emilsson, J. O’Dowd, S. Wang, R. Heyman and M. Cawthorne (1999). Effects of rexinoids and thiazolidinedione on levels of UCP isoforms and PGC-1 in the obese Zucker rat. Diabetologia 42, Suppl 1, A 206, Abs 774.

S.A. Smith, D. Boam, M.A. Cawthorne, J. Sidaway, M. Newman, M. Wilkinson, S. Dunmore, C.A. Lister (1998). Rosiglitazone reduces overexpression of insulin and amylin mRNA in hypertrophied pancreatic islets. Diabetologia 41, Suppl 1, A169, abs 659.

C.A.Lister, D. Boam, D. Bretherton-Watt, M.A. Cawthorne, G. Moore, S. Loughborough, J. Warrack, M. Wilkinson and S.A. Smith (1998). Rosiglitazone increases pancreatic islet cell area, number and insulin content, but not insulin gene expression. Diabetologia 41, Suppl 1, A169, abs 660.

A.L. Pallett, V. Emilsson, D. Coy, J. Taylor, C.-W. Woon and M.A. Cawthorne (1998). Reduced expression of somatostatin receptor sub-types in Zucker rat islets and functional typing of the somatostatin induced inhibition of insulin secretion. Diabetologia 41, Suppl 1, A152, abs 592.

V. Emilsson, J. Arch, R.P. De Groot, A.M. Kanu, Y-L. Liu, N.M. Morton, A.L. Pallett, C.A. Lister and M.A. Cawthorne (1998). A role for suppressors of leptin signalling in the states of leptin resistance. Presented at Symposium on Genetic and Molecular Basis of Obesity, Paris, 26-28 August 1998.

V. Emilsson, R.J. Summers, Y-L. Liu, A.M. Kanu, M.A. Cawthorne (1998). The effect of the b3-adrenoceptor agonist BRL 35135 on UCP-2 and UCP-3 mRNA levels in vivo. Presented at Symposium on Genetic and Molecular Basis of Obesity, Paris, 26-28 August 1998.

M.A. Cawthorne (1998). Thiazolidinediones in the treatment of Insulin Resistance Syndrome. Int. J. Obesity 22, Suppl 3, S86, abs O314.

M.A. Cawthorne, P.D. Chamberlain, K.H. Jennings, F. Paul, J. Cordell, A. Berry, S.D. Holmes, J. Park, J. Chambers, M.V. Sennitt, M.J. Stock, P.W. Young and G.J. Murphy (1998). Direct evidence of a b3-adrenoceptor expression in human adipose tissue, atrium and skeletal muscle obtained using a novel monoclonal antibody. Int. J. Obesity 22, Suppl 3, S74, abs O267.

M. Board and M.A. Cawthorne (1998). Abnormal response of glucose uptake by soleus muscle from ob/ob mice to BRL 37344. Int. J. Obesity 22, Suppl 3, S189, abs P355.

Y.-L. Liu, M.V. Sennitt, D.C. Hislop, D.L. Crombie, R.A. Heyman and M.A. Cawthorne (1998). Rexinoid X receptor agonists improve insulin sensitivity and have anti-obesity effects in Zucker fa/fa rats. Diabetes 47, Suppl 1, A283, abs 1099.

S.A. Smith, D. Boam, M.A. Cawthorne, J. Sidaway, M. Newman, M. Wilkinson, S. Dunmore, and C.A. Lister (1998). Rosiglitazone improves insulin sensitivity and reduces hyper-expression of insulin and amylin mRNAs in pancreatic islets. Diabetes 47, Suppl 1, A94. abs 0365.

S.A. Smith, D. Boam, D. Bretherton-Watt, M.A. Cawthorne, G. Moore, S. Loughborough, J. Warrack, M. Wilkinson and C.A.Lister (1998). Rosiglitazone increases pancreatic islet cell area, density and insulin content, but not insulin gene expression. Diabetes 47, Suppl 1, A18, abs 0072.

N.M. Morton, V. Emilsson, A.L. Pallett and M.A. Cawthorne (1998). Leptin signalling in pancreatic beta cells. British Diabetic Association, Edinburgh.

N.M. Morton, V. Emilsson and M.A. Cawthorne (1998). Interleukin 1b induces a novel STAT-DNA binding activity in the insulin secreting cell line Rin m5F. Keystone symposium on JAK and STAT signalling.

N.M. Morton, V. Emilsson, A.L. Pallett and M.A. Cawthorne (1997). Leptin-induced tyrosine phosphorylation in islets from ob/ob mice. Exp. Clin. Endocrinol. Diabetes 105, 4, A35.

A.L. Pallett, N.M. Morton, V. Emilsson and M.A. Cawthorne (1997). Effect of leptin on glucose stimulated insulin secretion in isolated rat islets. Exp. Clin. Endocrinol. Diabetes 105, 4, A41.

S. Pearson, M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B.T. Moore, S.A. Smith and Tadayyon, M. (1997). The insulin sensitiser, BRL 49653, increases expression of PPAR-g and aP2 mRNA but does not effect UCP or b3-AR mRNA. Int. J. Obesity 21, Suppl 2, 180, S61.

V. Emilsson, N. Cheung, M.V. Sennitt and M.A. Cawthorne (1997). Melanin concentrating hormone stimulates leptin secretion from adipocytes. Diabetologia 40, Suppl 1, 678, A173.

Y.L. Liu, V. Emilsson, and M.A. Cawthorne (1997). Inhibition of glycogen synthesis by leptin in isolated soleus muscle of obese (ob/ob) mice. Int. J. Obesity 21, Suppl 2, 23, S13.

M.A. Cawthorne, Y.L. Liu, Morton, N., Davenport, M. and Emilsson, V. (1997). Is there a role for leptin in the development of NIDDM? Diabetic Med.

Book Chapters, Specialist Report and Review

Ibrahim M, Jassim S, Cawthorne MA, Langlands (2013). A Pathway Enrichment and Gene Network Analysis Method for Biomarker Identification, Biotrinity Meeting 2013, Newbury, Berkshire, UK,  14-16 May 2013.

Ibrahim M, Jassim S, Cawthorne MA, Langlands K (2011). Pathway-based gene selection for disease classification. International Conference on Information Society (i-Society), London, UK, 360-365. full paper

Heald M, Cawthorne MA.  Dual acting and pan-PPAR activators as potential anti-diabetic therapies (2011).  Handb Exp Pharmacol. (203):35-51. Review. doi: 10.1007/978-3-642-17214-4_2

Arch JR (2011). Thermogenesis and related metabolic targets in anti-diabetic therapy. Handb Exp Pharmacol. (203):201-255. Review. doi: 10.1007/978-3-642-17214-4_10

Clapham JC, Arch JR (2011).  Targeting thermogenesis and related pathways in anti-obesity drug discovery.  Pharmacol Ther. 131(3):295-308.  Review. doi: 10.1016/j.pharmthera.2011.04.004

Ibrahim M, Jassim S, Cawthorne MA, Langlands K (2010). Topology-based pathway regulation score. International Symposium on Integrative Bioinformatics (6th annual meeting), Cambridge, UK, 22nd – 24th March 2010

Stocker CJ (ed.). Type 2 Diabetes: Methods and Protocols (London: Humana Press, 2009).

O’Dowd J. The isolation and purification of rodent pancreatic islets of Langerhans. In: Type 2 Diabetes: Methods and Protocols (London: Humana Press, 2009), ed. Stocker, C., pp37–42. doi:10.1007/978-1-59745-448-3_3

Nolan AL, O’Dowd J. The measurement of insulin secretion from isolated rodent islets of Langerhans. In: Type 2 Diabetes: Methods and Protocols (London: Humana Press, 2009), ed. Stocker, C., pp43–51. doi:10.1007/978-1-59745-448-3_4

Wargent ET. The measurement of insulin secretion using pancreas perfusion in the rodent. In: Type 2 Diabetes: Methods and Protocols (London: Humana Press, 2009), ed. Stocker, C., pp203–219. doi:10.1007/978-1-59745-448-3_14

Arch JRS. How might regulators’ expectations of novel anti-obesity drugs be achieved? The Diabetes Report. 2008 Jan: pp1–4.

Arch JRS. Thermogenesis and related targets for anti-obesity drugs. In: Obesity and Metabolic Disorders (Amsterdam: IOS Press, 2005), ed. Antel J., Finer N, Heal D and Krause G., pp143–160.

Cawthorne MA. Promising new targets for the next generation of anti-obesity drugs. In: Obesity and Metabolic Disorders (Amsterdam: IOS Press, 2005), ed. Antel J., Finer N, Heal D and Krause G., pp201–214.

Cawthorne MA, Heald M. Leptin (Amgen). Curr. Opin. Oncol. Endocrine Metabol. Invest. Drugs 2000 2: pp217–226.

Find Your Course

Subject:
Level:
Share on FacebookTweet about this on TwitterShare on StumbleUponShare on Google+Email this to someone